Genetic Analysis AS signs an agreement with ELTA90 Group to distribute and launch GA-map technology in the Balkan region

By | June 8, 2023

OSLO, NORWAY – June 8, 2023: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) has entered into a distribution agreement with ELTA90 Group (“ELTA90”), a rapidly growing Sofia-based distributor of laboratory diagnostics in the Balkan region with operations in various countries. One of the areas of interest of ELTA90 is specialized molecular diagnostics for the clinical diagnostics and research market.

Ronny Hermansen, CEO, Genetic Analysis, comments:
“GA is proud to have ELTA90 Group as a partner in the Balkan region and is excited to see our GA-map® platform gaining recognition from customers in new markets globally. The GA-map® platform offers a of high-throughput laboratory testing with an integrated cloud-based software algorithm for immediate presentation of microbiome analysis results.As regulatory requirements in Europe become more stringent, we are happy to see more and more laboratories appreciate our CE-IVD GA-map® solution.”

Market demand for gut microbiome assessments is rapidly increasing globally in private health services, medical clinics, and academic research with a focus on patient microbiota identification and classification. Together with ELTA90, GA can now offer its standardized gut microbiome testing platform to Balkan countries to meet the growing interest and raise awareness of the impact of microbiota alteration and dysbiosis.

Dr. Theodor Zamfirov, CEO, ELTA90 comments:
“E90 is excited to offer the GA-map® microbiome testing platform to our laboratory customers across the Balkan region as we see the demand for accurate and rapid microbiome testing is increasing rapidly. GA-map® will be a excellent complement to our growing specialty molecular diagnostics business, as several laboratories in the Balkan countries are focusing on supplying the European market with high quality diagnostics. The core value of ELTA90 is to offer the highest quality products to our customers and we are proud to add GA-map® to our high-end product portfolio.”

For more information, please contact:
Ronny Hermansen, managing director

Eilert Aamodt, Chief Financial Officer

Information about the ELTA90 group
ELTA90 is one of the largest distributors of life science and diagnostic products in the Balkans. ELTA90 was founded in 1999 and now consists of a team of 180 employees operating from 12 offices in 9 countries of the Balkan region. A major driving factor in our development has always been innovations in science and diagnostics.

The main focus of our business is the distribution of specialized laboratory equipment, reagents, consumables, diagnostic and research tests, often related to highly specialized activities such as NGS, in vitro fertilization, molecular genetic research.

Building on the foundation we have from traditional products in the laboratory furniture and equipment market, we have always sought to add to and expand our portfolio with innovative products of exceptional value for the patient and laboratory. The confidence to offer high quality brands in the market is a consequence of long-standing partnership relationships with companies such as Illumina, Sysmex, Stago, Nikon Instruments, Eppendorf, Thermo Fisher Scientific, Abbot and many others.

We are fully committed to the idea of ​​offering our customers comprehensive solutions in the field of immunology, clinical laboratory, microbiology, virology and rapid diagnostics. Among our priorities are automated solutions that give reliability and freedom of work to our customers.

For more information:

About Genetic Analysis:
Genetic Analysis AS (GA) is a science-based diagnostics company and a pioneer in the field of the human microbiome with over 15 years of experience in research and product development. The unique GA-map® platform is based on a predetermined multiplex target approach, specialized for the simultaneous analysis of large numbers of bacteria in a reaction. Test results are generated using the state-of-the-art clinically validated GA-map® software algorithm. This allows for immediate results without the need for additional bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to helping unblock and restore the human microbiome through its cutting-edge technology. GA employs a team of highly qualified employees with scientific backgrounds and expertise in bioinformatics, molecular biology and bioengineering.

For more information:

Interested in learning more about GA products? Please visit–technolog ,c3782729

(c) 2023 Cision. All rights reserved., source Press Releases – Italian

#Genetic #Analysis #signs #agreement #ELTA90 #Group #distribute #launch #GAmap #technology #Balkan #region

Leave a Reply

Your email address will not be published. Required fields are marked *